How much platinum-based chemotherapy is enough in NSCLC?

被引：0
|
作者：
Solange Peters
Alex A. Adjei
机构：
[1] Centre Hospitalier Universitaire Vaudois (CHUV),Oncology Department
[2] Roswell Park Cancer Institute,undefined
来源：
Nature Reviews Clinical Oncology | 2015年 / 12卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
With no large randomized phase III trials to provide definitive answers, the ideal number of platinum-based chemotherapy cycles in patients with advanced non-small-cell lung cancer has long been unclear. Most guidelines recommend a maximum of 4–6 cycles. Rossi and colleagues now suggest that four chemotherapy cycles is the optimal regimen.
引用
收藏
页码：8 / 10
页数：2
相关论文
共 50 条
  • [11] Pharmacogenomics of platinum-based chemotherapy response in NSCLC: a genotyping study and a pooled analysis
    Chen, Juan
    Wang, Zhan
    Zou, Ting
    Cui, Jiajia
    Yin, Jiye
    Zheng, Wei
    Jiang, Wuzhong
    Zhou, Honghao
    Liu, Zhaoqian
    ONCOTARGET, 2016, 7 (34) : 55741 - 55756
  • [12] Pembrolizumab as a Monotherapy or in Combination With Platinum-Based Chemotherapy in NSCLC: Correlation With Blood Biomarkers
    Holtzman, L.
    Moskovitz, M.
    Urban, D.
    Wollner, M.
    Nechushtan, H.
    Rainhorn, D.
    Zer, A.
    Shochat, T.
    Bar, J.
    Rottenberg, Y.
    Dudnik, E.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S964 - S964
  • [13] Anthracycline adjuvant chemotherapy: How much is enough?
    Levine, MN
    Eisen, A
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (03) : 599 - 601
  • [14] Advanced NSCLC chemotherapy: how much and how long?
    Belani, Chandra P.
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S287 - S287
  • [15] Treatment on advanced NSCLC: Platinum-based chemotherapy plus erlotinib or platinum-based chemotherapy alone? A systematic review and meta-analysis of randomised controlled trials
    Zhou, Jian-Guo
    Tian, Xu
    Wang, Xue
    Tian, Jin-Hui
    Wang, Yi
    Wang, Fei
    Zhang, Yu
    Ma, Hu
    MEDICAL ONCOLOGY, 2015, 32 (02)
  • [16] Treatment on advanced NSCLC: Platinum-based chemotherapy plus erlotinib or platinum-based chemotherapy alone? A systematic review and meta-analysis of randomised controlled trials
    Jian-Guo Zhou
    Xu Tian
    Xue Wang
    Jin-Hui Tian
    Yi Wang
    Fei Wang
    Yu Zhang
    Hu Ma
    Medical Oncology, 2015, 32
  • [17] COMPARISON OF GEFITINIB AND PLATINUM-BASED CHEMOTHERAPY AND ONLY PLATINUM-BASED CHEMOTHERAPY TO TREAT LUNG ADENOCARCINOMA
    Yang, L.
    Fan, J. H.
    Liu, L. L.
    Su, Y.
    Lu, D.
    Huang, J. Y.
    Zhang, H.
    Li, Y.
    Huo, H. D.
    Du, Z. H.
    Liu, G. T.
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2018, 32 (03): : 613 - 618
  • [18] Dissecting genomic determinants of response to platinum-based chemotherapy in advanced NSCLC and colorectal cancer
    Mo, Shirley S.
    Liu, David
    Gray, Stacy W.
    Joffe, Steven
    Wagle, Nikhil
    Garber, Judy
    Garraway, Levi A.
    Sholl, Lynette
    Janne, Pasi A.
    Van Allen, Eliezer M.
    CANCER RESEARCH, 2018, 78 (13)
  • [19] Avelumab after platinum-based chemotherapy
    Niegisch, G.
    Worst, T. S.
    UROLOGE, 2021, 60 (05): : 640 - 641
  • [20] The resurgence of platinum-based cancer chemotherapy
    Kelland, Lloyd
    NATURE REVIEWS CANCER, 2007, 7 (08) : 573 - 584
12345